VYNE Therapeutics (VYNE) Liabilities and Shareholders Equity (2016 - 2026)

VYNE Therapeutics' Liabilities and Shareholders Equity history runs 11 years deep, the most recent figure standing at $25.9 million for Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 54.14% year-over-year to $25.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $157.2 million (down 45.08% YoY) and the FY2025 annual result came in at $30.2 million, down 54.92% from the prior year.
• Liabilities and Shareholders Equity was $25.9 million for Q1 2026 at VYNE Therapeutics, down from $30.2 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $97.7 million in Q4 2023 and bottomed at $19.3 million in Q3 2023.
• A 5-year average of $53.9 million and a median of $51.0 million in 2022 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity plunged 58.93% — and 2024, when it surged 295.48%.
• VYNE Therapeutics' Liabilities and Shareholders Equity stood at $40.8 million in 2022, then jumped by 139.67% to $97.7 million in 2023, then tumbled by 31.51% to $66.9 million in 2024, then plunged by 54.92% to $30.2 million in 2025, then slipped by 14.21% to $25.9 million in 2026.
• Business Quant data shows VYNE's Liabilities and Shareholders Equity at $25.9 million in Q1 2026, $30.2 million in Q4 2025, and $44.7 million in Q2 2025.